Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Section 3 of 6

Product information and disease description

367 evidence topics · 136 sources

Product description

Phase of product development

Summary: regulatory status and development history
  • Approval: the FDA approved Lembaz (adrabetadex) injection under NDA 220996 on November 17, 2026, as a “Type 1 - New Molecular Entity” with priority review and orphan status. The FDA describes it as the first treatment shown to help people with a “severe form of Niemann-Pick disease type C (NPC) live longer”. Beren Therapeutics states that LEMBAZ will be available at commercial treatment sites nationwide in early December.
  • Application and review: Beren Therapeutics, through its subsidiary Mandos LLC, submitted the NDA on December 17, 2025 for the treatment of patients with infantile-onset NPC. The application was based on an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives. The FDA granted priority review and assigned a PDUFA target action date of August 17, 2026. Beren's March 18, 2026 response to an FDA information request was classified as a major amendment, which extended the goal date by three months to November 17, 2026. The application was not referred to an FDA advisory committee.
  • Designations: the FDA designated 2-hydroxypropyl-B-cyclodextrin an orphan drug for the treatment of Niemann Pick disease, type C on 02/18/2013, with Mandos LLC as the sponsor. The European Commission granted orphan designation EU/3/13/1124 on 26 April 2013 to the International Niemann-Pick Disease Alliance; sponsorship was transferred to Vtesse Europe Limited in February 2015, Mallinckrodt Pharmaceuticals Ireland Limited in September 2018, Rapport Global Strategic Services Ireland Limited in December 2021, and Eliquent Life Sciences Limited in August 2024. Adrabetadex also holds rare pediatric disease designation. The FDA granted Vtesse Breakthrough Therapy designation for VTS-270 in Niemann-Pick Type C1 disease on January 6, 2016 and later rescinded it based on data from a 12-month phase 2b/3 trial; a second Breakthrough Therapy designation, for infantile-onset NPC, was announced on December 9, 2025 and was informed by an externally controlled survival analysis.
  • Priority review voucher and patents: the FDA granted a rare pediatric disease priority review voucher (PRV NDA 220996) with the approval, which may be transferred, including by sale. Earlier agreements refer to shares of voucher proceeds: Sucampo agreed in 2017 to pay Vtesse shareholders a share of net proceeds from monetization of the voucher, and the Mallinckrodt plan of reorganization refers to the Debtors' 63% retained ownership interest in the voucher. Beren states that its intellectual property estate provides patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates, and that it holds more than 30 issued U.S. patents.
  • Development history: researchers at the NIH National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with Vtesse, developed VTS-270. After its launch in January 2015, Vtesse fully enrolled the registrational study at 20 clinical trial sites. Sucampo acquired Vtesse on April 3, 2017 for upfront consideration of $200 million plus contingent royalties, and Mallinckrodt acquired Sucampo, and with it VTS-270, in February 2018. At a Type A meeting in August 2018, the FDA indicated that approvability would be based on the totality of data; in November 2018 Mallinckrodt announced that the registration trial did not show a statistically significant separation from placebo. In the three months ended December 27, 2019, Mallinckrodt recognized a full impairment of $274.5 million on the VTS-270 asset, “primarily driven by continued regulatory challenges”, and trial NCT03643562 ended after the sponsor determined that the benefit-risk profile of adrabetadex was not favorable. Mandos acquired the program from Mallinckrodt in 2021, held an introductory call and a Type C meeting with the FDA, and completed new analyses of adrabetadex before the NDA submission.
  • Earlier timelines: in April 2017 Sucampo expected pivotal trial results in mid-2018 and a launch beginning in 2019, and a YODA Project data request projected an NDA submission by December 2023 toward accelerated approval.
Orphan drug designation in the United States, February 2013

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Material safety data sheet

No evidence found.

Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
  • Price basis: no wholesale acquisition cost (WAC) or list price for adrabetadex (Lembaz) had been published as of 18 November 2026, the date of the latest source; trade press reporting on the approval states that list pricing had not been announced.
  • Dosing basis: per the prescribing information, adrabetadex is supplied as one 900 mg/4.5 mL single-dose vial per carton and is administered intrathecally every two weeks, with an age-based starting dose and upward titration to a weight-based maximum of 600 mg every two weeks (7 kg to less than 12 kg) or 900 mg every two weeks (12 kg or more). Every labeled dose is at or below 900 mg, so each administration uses one vial, assuming a whole vial per administration as the label gives no other basis. Every two weeks is 26 administrations, and therefore 26 vials, per year; the manufacturer's out-of-pocket program terms also cap support at 26 doses per year.
  • Base case: not calculable, because no price has been published.
  • Range: not calculable. With one vial per administration, annual drug cost will equal 26 times the vial price at every labeled dose and weight band, and monthly cost will equal annual cost divided by 12.
  • Rationale for the range: the label varies the dose by age, body weight, audiology results, and dose reductions for ataxia or fatigue, but no labeled dose exceeds the content of one vial, so these sources of variation change the volume administered and leave the number of vials unchanged under the whole-vial assumption.
  • Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

ATC classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Cerebrospinal fluid and plasma pharmacokinetics after intracerebroventricular dosing in the NIH phase 1 trial

“Three NPC1 subjects were admitted to the NIH Clinical Center Intensive Care Unit and an Ommaya reservoir was surgically placed on the nondominant side.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following the ICV injection of 50 mg HP-β-CD, high CSF concentrations of HP-β-CD were observed with the Cmax ranging from approximately 520 to 1,500 μg/ml in three patients (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean Vdss of ∼130 ml was approximately to the reported CSF volume in humans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated mean t1/2 for HP-β-CD in CSF was 6.58 h based on the RP-UPLC-MS/MS method and 10.1 h based on the 2D-LC-IF-MS/MS method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean Cmax and AUC of HP-β-CD in plasma were less than 0.3% of the corresponding CSF PK parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated mean t1/2 values for HP-β-CD in plasma were 12.4 h based on the RP-UPLC-MS/MS method and 15.1 h based on the 2D-LC-IF-MS/MS method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Common adverse reactions through Week 52 in Trial 1 Parts A and B
Preferred termAdrabetadex up to 900 mg (N=32), n (%)Sham (N=18), n (%)
Hearing impairment“23 (71.9)”“8 (44.4)”
Ataxia“22 (68.8)”“5 (27.8)”
Fatigue“18 (56.3)”“5 (27.8)”
Vomiting“17 (53.1)”“3 (16.7)”
Back pain“16 (50.0)”“3 (16.7)”
Headache“14 (43.8)”“3 (16.7)”
Pyrexia“13 (40.6)”“3 (16.7)”
Diarrhea“10 (31.3)”“1 (5.6)”
Nausea“8 (25.0)”“1 (5.6)”
Cough“8 (25.0)”“4 (22.2)”
Contusion“6 (18.8)”“2 (11.1)”
Pain in extremity“6 (18.8)”“1 (5.6)”
Epistaxis“5 (15.6)”“1 (5.6)”
Urinary incontinence“5 (15.6)”“1 (5.6)”
Muscular weakness“5 (15.6)”“0 (0)”
Dysarthria“4 (12.5)”“1 (5.6)”
Skin abrasion“4 (12.5)”“1 (5.6)”
Nasopharyngitis“4 (12.5)”“2 (11.1)”
Ototoxicity of 2-hydroxypropyl-beta-cyclodextrin across species: review

“Despite the potential health benefits, use of HPβCD has been linked to significant hearing loss in several species, including humans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ototoxicity can occur following central or peripheral drug delivery, with either route resulting in the preferential loss of cochlear outer hair cells (OHCs) within hours of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The long-term impact of HPβCD use as a maintenance drug, and the mechanism(s) of ototoxicity, are unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Yet, Kleptose HPB (aka VTS-270) is ototoxic in mice and humans (Davidson et al., 2016; Ory et al., 2017).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, seemingly innocuous doses can become devastating to the ear if administered by different routes close in time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The risk for functionally significant hearing loss before development of speech and language should be weighed carefully with potential benefits of early-life treatment of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Adrabetadex
Effects of Adrabetadex on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Effect of Adrabetadex on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1
Adverse reactionMIPLYFFA with miglustat, N=26, n (%)Placebo with miglustat, N=13, n (%)
Upper respiratory tract infection“8 (31)”“2 (15)”
Diarrhea“6 (23)”“3 (23)”
Decreased weight“4 (15)”“0”
Lower respiratory tract infection“3 (12)”“1 (8)”
Levacetylleucine: recommended dosage by body weight
Body weightMorning doseAfternoon doseEvening dose
15 kg to less than 25 kg“1 gram”“No Dose”“1 gram”
25 kg to less than 35 kg“1 gram”“1 gram”“1 gram”
35 kg or more“2 grams”“1 gram”“1 gram”
Levacetylleucine: adverse reactions in NPC at an incidence of 5% or more in Treatment Period I of Trial 1
Adverse reactionAQNEURSA, N=30, n (%)Placebo, N=30, n (%)
Upper respiratory tract infection“5 (17)”“1 (3)”
Abdominal pain“2 (7)”“0 (0)”
Dysphagia“2 (7)”“0 (0)”
Vomiting“2 (7)”“0 (0)”
Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years
Body surface area (m2)Recommended dose
More than 1.25“200 mg three times a day”
More than 0.88 to 1.25“200 mg twice a day”
More than 0.73 to 0.88“100 mg three times a day”
More than 0.47 to 0.73“100 mg twice a day”
0.47 or less“100 mg once a day”
Miglustat: European Union contraindications, warnings, and precautions

“Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.” (opens the source at this quote in a new tab)

“Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.” (opens the source at this quote in a new tab)

“Gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8).” (opens the source at this quote in a new tab)

“Cases of Crohn’s disease have been reported post-marketing in Niemann-Pick type C disease patients treated with Zavesca.” (opens the source at this quote in a new tab)

“Reliable contraceptive methods should be maintained while male patients are taking Zavesca and for 3 months following discontinuation.” (opens the source at this quote in a new tab)

“The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca.” (opens the source at this quote in a new tab)

“In patients included in the clinical trial, 40%-50% had platelet counts below the lower limit of normal at baseline. Monitoring of platelet counts is recommended in these patients.” (opens the source at this quote in a new tab)

“Growth should be monitored in paediatric and adolescent patients during treatment with Zavesca; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy.” (opens the source at this quote in a new tab)

Place of product in therapy

Disease description

Definition and etiology
Proportion of cases attributed to NPC1 and NPC2
GeneProportion of NPC attributed to pathogenic variants in gene
NPC1“95%”
NPC2“5%”
Epidemiology
Incidence of Niemann-Pick disease type C
Distribution of clinical forms in eight national and international cohorts
CohortAcute perinatal form (%)Early infantile neurological onset (%)Late infantile neurological onset (%)Juvenile neurological onset (%)Adult neurological onset (%)Total no.
France and European countries“12”View highlighted excerpt for this quote“30”View highlighted excerpt for this quote“23”View highlighted excerpt for this quote“30”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“125”View highlighted excerpt for this quote
Spain“7”View highlighted excerpt for this quote“37”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“25”View highlighted excerpt for this quote“11”View highlighted excerpt for this quote“57”View highlighted excerpt for this quote
Italy“7”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“32”View highlighted excerpt for this quote“23”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“43”View highlighted excerpt for this quote
France“9”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“22”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“107”View highlighted excerpt for this quote
Germany“3”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“35”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“37”View highlighted excerpt for this quote
Czech Republic“6”View highlighted excerpt for this quote“17”View highlighted excerpt for this quote“24”View highlighted excerpt for this quote“37”View highlighted excerpt for this quote“17”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote
UK“5”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“39”View highlighted excerpt for this quote“32”View highlighted excerpt for this quote“19”View highlighted excerpt for this quote“132”View highlighted excerpt for this quote
European countries“—”View highlighted excerpt for this quote“11”View highlighted excerpt for this quote“31”View highlighted excerpt for this quote“31”View highlighted excerpt for this quote“27”View highlighted excerpt for this quote“145”View highlighted excerpt for this quote
Prevalence of Niemann-Pick disease type C
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Guideline statements on suspicion, biomarker screening, and genetic confirmation

“Statement #9: The signs and symptoms of NPC are nonspecific, which may lead to misdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, the presence of cataplexy and/or saccadic eye movement abnormalities should raise suspicion of NPC and help differentiate NPC from other neurodegenerative disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Statement #12: Biomarker assessment should be considered the first‐line test to screen for NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Three classes of biochemical markers are currently in use (oxysterols, PPCS, and lyso‐SM) or development (bile acid derivatives).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Typically, the diagnosis must be confirmed by deoxyribonucleic acid (DNA) sequencing, although diagnostic routes depend on tool availability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Statement #13: Any individual whose diagnosis of NPC is considered based on their clinical manifestation and/or abnormal biomarker profile should undergo genetic testing for NPC genes to confirm the diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Referral to a clinical geneticist or genetic counselor should be considered following NPC diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Newborn screening: status and bile acid dried blood spot assay
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Niemann-Pick disease type C
Humanistic burden and health-related quality of life
Survey and interviews of caregivers and adult patients in the United States and United Kingdom
Economic burden and healthcare resource utilization
U.S. claims-based cost and resource use study of Niemann-Pick disease type C

No evidence found.

Economic impact of Niemann-Pick disease type C on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Miglustat
Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States
Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort

“Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Children showed an improvement in HSEM velocity of similar size at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Survival with and without miglustat: pooled national cohorts and the NPC Registry

“Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Swallowing outcomes in a single-center cohort with neurological onset before age 15 years

“Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Infantile onset: French pediatric cohort treated in clinical practice
Early infantile onset: French retrospective comparison of treated and untreated patients
Levacetylleucine
Open-label extension at 12 and 18 months compared with a historical cohort

“Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Arimoclomol
Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint

“In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fifty patients enrolled; 42 completed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information
R4DNPCCSS scoreMIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12)Placebo with miglustat (N=13 at baseline, N=12 at month 12)
Baseline, mean (SD)“8.9 (6.1)”“7 (5.8)”
Change from baseline to month 12, mean (SD)“-0.2 (1)”“1.9 (3.4)”
Change from baseline to month 12, LS mean (SE)“-0.2 (0.5)”“2 (0.7)”
Placebo-subtracted difference (95% CI)“-2.2 (-3.8, -0.6)”Not applicable
Regulatory status outside the United States: refusal of European Union marketing authorisation confirmed in November 2026
Other cyclodextrin products
Compassionate use of intrathecal and intracerebroventricular HPβCD in Japan
Supportive and symptomatic care
Transplantation and investigational therapies
Limitations of current therapies
Summary
  • No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
  • Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
  • Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
  • Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
  • Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
  • Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
  • Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
  • Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.
Place in treatment, anticipated use, and care setting
Summary
  • Indication: LEMBAZ is indicated to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in pediatric patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older.
  • Position relative to other therapies: before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. In the label's integrated survival analysis, longer overall survival was observed independent of baseline miglustat use. Published recommendations state that all patients with a confirmed diagnosis should be considered for miglustat, those with neurological symptoms for levacetylleucine, and those with neurological symptoms on background miglustat for arimoclomol; more than 75% of participants in the arimoclomol and levacetylleucine pivotal trials were taking miglustat. The company describes adrabetadex as “a foundational therapy that can be safely combined with other approved NPC treatments”, based on a safety profile generally similar with and without additional therapies.
  • Anticipated use: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that early intervention can make the greatest difference.
  • Care setting: LEMBAZ is administered intrathecally every two weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures, with local anesthetic and sedation as indicated by the patient's clinical condition. A comprehensive audiology evaluation is performed before use. Lembaz is exclusively available through CuraScript SD by Evernorth and is billed in medical buy-and-bill settings without a product-specific HCPCS code. Published recommendations call for referral to a center with expertise in NPC wherever possible.
Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA
Ongoing post-approval monitoring
Registered post-approval studies

No evidence found.

Expected outcomes of therapy
Summary
  • Treatment goals: disease-modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and extending lifespan beyond that predicted by natural history data. Treatment goals are established at diagnosis and reviewed regularly, aiming to improve or maintain physical and psychosocial wellbeing.
  • Survival in the label analysis: the FDA examined the survival of 36 participants treated with Lembaz across three clinical studies and an expanded access program against a matched external control group. Deaths occurred in 12 (33.3%) LEMBAZ-treated participants and 24 (66.9%) controls; the hazard ratio for death was 0.45 (95% CI 0.21, 0.95), a 55% reduction in the risk of death, and median survival was 8.5 years with treatment and 4.9 years in controls. Longer overall survival was observed independent of baseline miglustat use.
  • Survival in a separate company analysis: deaths occurred in 17 (23.6%) adrabetadex-treated participants and 44 (61.2%) external controls, with a hazard ratio of 0.289 (95% CI 0.141, 0.593; P < 0.0001), reported by the company as a 71% reduction in the risk of mortality; the 5-year survival rate was 84% with adrabetadex and 42% in external controls.
  • Disease progression: in a company analysis of 79 treated participants, the annual rate of progression on the rescored 4-domain NPCCSS fell from 1.34 units/year before treatment to 0.76 units per year after treatment, a 43% reduction (P=0.0055). An observational cohort receiving routine clinical care progressed by 1.5 units/year on the 5-domain NPCCSS. The company approval announcement states: “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”. Among five individuals treated with intrathecal HPBCD for 4 to 11 years, some disease progression continued.
  • Expected harm: treatment with LEMBAZ has resulted in permanent hearing impairment; 37% (22/59) of patients in Trial 3 and an expanded access program experienced hearing impairment.